Methods and Difficulties in the Creation of the 2019 Coronavirus Disease Vaccine
Keywords:
SARS-CoV-2, Vaccine development, Clinical trialsAbstract
The novel coronavirus infection (coronavirus disease-2019 (COVID-19)) emerged from Wuhan in the Hubei Province of China in late 2019. Millions of people were infected with COVID-19 pandemic due to the long incubation period of the virus inside the human body and the dearth of available treatments or vaccines. High transmission rates created havoc, which highlighted the urgent need for effective interventions to stop the spread and clinical impact of the virus on patients and populations. Previous research on severe acute respiratory syndrome coronavirus (SARS-CoV) provides information on vaccination strategies that could inform how governments approach the elimination of this novel coronavirus. Numerous efforts have been made to develop vaccines against Middle East respiratory syndrome (MERS) and SARS. The spike glycoprotein or S protein is the critical target for most of the drugs and vaccines against coronavirus. The virus uses the spike (S) protein for entering the host cell, by interacting with the receptor called angiotensin converting enzyme-2 (ACE2). Various vaccine platforms are available such as nucleic acid vaccine, protein-based vaccines, virus-vectored vaccines and live or attenuated vaccines, with each having their advantages and disadvantages. This review focuses on the overview of different vaccine candidates used, those currently in development, and the challenges encountered while developing effective vaccines.
References
Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (London). 2020; 20: 124-127. doi: 10.7861/clinmed.2019-coron
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020; 382: 1708-1720. doi: 10.1056/NEJMoa2002032
Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Eng J Med. 2014; 370: 2499-2505. doi: 10.1056/NEJMoa1401505
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic char-acterisation and epidemiology of 2019 novel coronavirus: Impli-cations for virus origins and receptor binding. Lancet. 2020; 395: 565-574. doi: 10.1016/S0140-6736(20)30251-8
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579: 265-269. doi: 10.1038/s41586-020-2008-3
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of prob-able bat origin. Nature. 2020; 579: 270-273. doi: 10.1038/s41586- 020-2012-7
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on de-cade – long structural studies of SARS coronavirus. J Virol. 2020; 94: e00127-20. doi: 10.1128/JVI.00127-20
Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19: 305-306. doi: 10.1038/d41573-020-00073-5
He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly po-tent neutralizing antibodies: Implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004; 324: 773-781. doi:
1016/j.bbrc.2004.09.106 10. Le Coupanec A, Desforges M, Meessen-Pinard M, Dube M, Day R, Seidah NG, et al. Cleavage of a neuroinvasive human re-spiratory virus spike glycoprotein by proproteinconvertases modu-lates neurovirulence and virus spread within the central nervous system. PLoS Pathogens. 2015; 6: 11,e1005261. doi: 10.1371/journal. ppat.1005261
Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, et al. Pre-fusion structure of a human corona-virus spike protein. Nature. 2016; 531: 118-121. doi: 10.1038/na-ture17200
Walls AC, Tortorici MA, Snijder J, Xiong X, Bosch BJ, Rey FA. et al., Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proceedings of the National Academy Sciences of the United States of America. 2017; 114: 11157- 11162.
Bassi DE, Zhang J, Renner C, Klein-Szanto AJ. Targeting proproteinconvertases in furin-rich lung cancer cells results in de-creased in vitro and in vivo growth. Mol Carcinog. 2017; 56: 1182- 1188. doi: 10.1002/mc.22550
Gupta P. A review: Epidemiology, pathogenesis and pros-pect in developing vaccines for novel Coronavirus (COVID-19). Indian Journal of Tuberculosis. 2021; 68: 92-98. doi: 10.1016/j. ijtb.2020.09.021
Li H, Wang Y, Xu J, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43: E002. doi: 10.3760/cma. j.issn.1001-0939.2020.0002
Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronavirus. Front Microbiol. 2020; 11: 298. doi: 10.3389/fmicb.2020.00298
Munjal A, Khandia R, Dhama K, Sachan S, Karthik K, Tiwari R. et al. Advances in developing therapies to combat Zika virus: Current knowledge and future perspectives. Front Immunol. 2017; 8: 1469. doi: 10.3389/ fmicb.2017.01469
Singh RK, Dhama K, Chakraborty S, Tiwari R, Natesan S, Khandia R, et al. Nipah virus: Epidemiology, pathology, immuno-biology and advances in diagnosis, vaccine designing and control strategies-a comprehensive review. Veterinary Quaterly. 2019; 39(1): 26-55. doi: 10.1080/01652176.2019.1580827
Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef SK, et al. Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus. Front Immunol. 2018; 9: 1803. doi: 10.3389/fimmu.2018.01803
Graham RL, Donaldson EF, Baric RS. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat Rev Micro-biol. 2013; 11(12): 836-848.
World Health Organization (WHO). Draft landscape of COVID-19 candidate vaccines. Website. https://www.who.int/ publications/m/item/draft-landscape-of-covid-19-candidate-vac-cines. Accessed February 12, 2021.
Callaway E. The race for coronavirus vaccines: A graphi-cal guide. Nature. 2020; 580: 576-577. doi: 10.1038/d41586-020- 01221-y
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807): 215-220. doi: 10.1038/s41586- 020-2180-5
Li F, Li W, Farzan M, Harrison SC. Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309(5742): 1864-1868. doi: 10.1126/ science.1116480
Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004; 78(22): 12672-12676. doi: 10.1128/JVI.78.22.12672-12676.2004
Wang C, Li W, Drabek D, Okba NMA, Van Haperen R, Os-terhaus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11: 2251. doi: 10.1038/ s41467-020-16256-y
Ozkan K. How close are we to a Covid-19 vaccine. Journal of Pure and Applied Microbiology. 2020; 14: 893-902. doi: 10.22207/ JPAM.14.SPL1.26
Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines. 2020; 5: 18. doi: 10.1038/s41541-020-0170-0
Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immuniza-tion against hepatitis B. Int J Pharm. 2008; 354(1-2): 235-241. doi: 10.1016/j.ijpharm.2007.11.027
Lee J, Kumar SA, Jhan YY, Bishop CJ. Engineering DNA vac-cines against infectious diseases. Acta Biomater. 2018; 80: 31-47. doi: 10.1016/j.actbio.2018.08.033
Lurie N, Saville M, Hatchett R, Halton J. Developing COV-ID-19 vaccines at pandemic speed. N Eng J Med. 2020; 382: 1969- 1973.
Amanat F, Krammer F. SARS-CoV-2 vaccine: Status report. Im-munity. 2020; 52: 583-589. doi: 10.1016/j.immuni.2020.03.007
Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and im-pact of intramuscular electroporation for delivery. J Infect Dis. 2013; 208(5); 818-829. doi: 10.1093/infdis/jit236
Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respira-tory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015; 19(7): 301ra132. doi: 10.1126/ scitranslmed.aac7462
Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, et al. Immunogenicity and protective efficacy of a vaxfectin-ad-juvanted tetravalent dengue DNA vaccine. Vaccine. 2012; 30: 336- 341. doi: 10.1016/j.vaccine.2011.10.085
Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fa-gone P, Ramanathan AA, et al. A DNA vaccine against chikungu-nya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Neglected Tropical Diseases. 2011; 5: e928. doi: 10.1371/journal. pntd.0000928
Mahase E. Covid-19: what do we know so far about a vaccine? BMJ. 2020; 369: m1679. doi: 10.1136/bmj.m1679 Gupta P
Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Develop-ing mRNA-vaccine technologies. RNA Biology. 2012; 9: 1319-1330. doi: 10.4161/rna.22269
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17: 261-279. doi: 10.1038/nrd.2017.243
Du L, Zhao G, Chan CCS, Sun S, Chen M, Liu Z. et al. Re-combinant receptor- binding domain of SARS-CoV spike pro-tein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009; 393: 144-150. doi: 10.1016/j.virol.2009.07.018
Oscherwitz J. The promise and challenge of epitope fo-cused vaccines. Hum Vaccin Immunother. 2016; 12: 2113-2116. doi: 10.1080/21645515.2016.1160977
Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010; 10: 787-796. doi: 10.1038/nri2868
Caivano A, Doria-Rose NA, Buelow B, Sartorius R, Trovato M, D’Apice L, et al. HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillusstearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNg production by CD4+ T cells. Virology. 2010; 407: 296-305. doi: 10.1016/j.virol.2010.08.026
Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines. 2020; 8: 153. doi: 10.3390/vaccines8020153
Jimenez-Guardeno JM, Regla-Nava JA, Nieto-Torres JL, DeDiego ML, Castano-Rodriguez C, Fernandez-Delgado R, et al. Identification of the mechanisms causing reversion to virulence in an attenuated SARS- CoV for the design of a genetically stable vaccine. PLoS Pathogen. 2015; 11: e1005215. doi: 10.1371/journal. ppat.1005215
Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014; 111: 12283-12287. doi: 10.1073/pnas.1400472111
Almazan F, DeDiego ML, Sola I, Zuniga S, Nieto-Torres JL, Marquez-Jurado S. Engineering a replication- competent, propa-gation- defective middle east respiratory syndrome coronavirus as a vaccine candidate. mBio. 2013; 4(5): e00650-13. doi: 10.1128/ mBio.00650-13
Hou Y, Meulia T, Gao X, Saif LJ, Wang Q. Deletion of both the tyrosine- based endocytosis signal and the endoplasmic reticulum retrieval signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs. J Virol. 2018; 93: e01758- 18. doi: 10.1128/JVI.01758-18
Cheng BYH, Ortiz- Riano E, Nogales A, de la Torre JC, Mar-tínez-Sobrido L. Development of live- attenuated arenavirus vac-cines based on codon deoptimization of the viral glycoprotein. J Virol. 2015; 89: 3523–3533. doi: 10.1016/j.virol.2016.11.001
Mueller S, Stauft CB, Kalkeri R, Koidei F, Kushnir A, Tasker S, et al. A codon- pair deoptimized live attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. Vaccine. 2020; 38: 2943-2948. doi: 10.1016/j.vac-cine.2020.02.056
Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmo-nary response upon challenge. J Virol. 2011; 85: 12201-12215. doi: 10.1128/JVI.06048-11
Lauring AS, Jones JO, Andino R. Rationalizing the develop-ment of live attenuated virus vaccines. Nat Biotechnol. 2010; 28: 573-579. doi: 10.1038/nbt.1635
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Develop-ment of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020; 369: 77-81. doi: 10.1126/science.abc1932
Clinical trials.gov. Website. https://clinicaltrials.gov/ct2/ show/NCT04456595?term=vaccine&cond=covid-19&draw=2. Accessed May 4, 2021.
Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010; 8: 62-73. doi: 10.1038/ nrmicro2240 Submit your article to this journal | https://openventio.org/submit-manuscript/
Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology. 2018; 153: 1-9. doi: 10.1111/imm.12829
Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dor-rell L. Viral vectors as vaccine platforms: From immunogenic-ity to impact. Curr Opin Immunol. 2016; 41: 47-54. doi: 10.1016/j. coi.2016.05.014
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovi-rus type-5 vectored COVID-19 vaccine: A dose- escalation, open-label, non- randomised, first- in-human trial. Lancet. 2020; 395: 1845-1854. doi: 10.1016/S0140-6736(20)31208-3
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Ram-merstorfer SB, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: A preliminary report of a phase 1/2, single- blind, randomised controlled trial. Lancet. 2020; 396(10249): 467-478. doi: 10.1016/S0140-6736(20)31604-4
Iwasaki A, Yang Y. The potential danger of suboptimal anti-body responses in COVID-19. Nat Rev Immunol. 2020; 20: 339-341. doi: 10.1038/s41577-020-0321-6
Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS vi-rus. PLoS One. 2012; 7: e35421. doi: 10.1371/journal.pone.0035421
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Epidemiology (EOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
